# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000886163-18-000056
Filing Date
2018-04-30
Accepted
2018-04-30 16:08:25
Documents
11
Period of Report
2018-04-27
Effectiveness Date
2018-04-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | lgnd-2018annualmeetingproxy.htm | DEF 14A | 916603
2 |  | a02szebligandpharmaceuti001.jpg | GRAPHIC | 225041
3 |  | a02szebligandpharmaceuti002.jpg | GRAPHIC | 103067
4 |  | a02szicligandpharmaceuti001.jpg | GRAPHIC | 206421
5 |  | a02szicligandpharmaceuti002.jpg | GRAPHIC | 160119
6 |  | image0.jpg | GRAPHIC | 9775
7 |  | image1a01.gif | GRAPHIC | 565
8 |  | image2.gif | GRAPHIC | 1174
9 |  | image3.gif | GRAPHIC | 612
10 |  | image4.gif | GRAPHIC | 431
11 |  | stockreturngraph2017.jpg | GRAPHIC | 86451
| Complete submission text file | 0000886163-18-000056.txt |  | 1998717

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33093 | Film No.: 18789737
SIC: 2834 Pharmaceutical Preparations